CD274 and breast carcinoma: This may be explained, in part, by lower expression of PD-L1 and TILs, with only 15% of HR+ breast cancer expressing PD-L1 CPS > 10.[30] There are no FDA-approved immunotherapies in HR + breast cancer to date.